Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Non-current Liabilities
All obligations due after more than one year.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $0, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 15.25M | — |
Total Non-current Liabilities vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total non-current liabilities of $0 is the lowest of the 11 companies compared; the peer median is $53.48M.
- Total non-current liabilities amounts to 0.0% of total assets for NVCT, versus a peer median of 3.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.32B | +88832.8% | -8.4% | 1.5% | |
| Jun 2026 | $403.88M | +94.2% | +275.6% | 54.2% | |
| Mar 2026 | $344.87M | +4.2% | +681.8% | 73.0% | |
| Mar 2026 | $100.74M | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $79.19M | -38.4% | +65.1% | 34.8% | |
| Mar 2026 | $27.78M | +33.5% | -1.3% | 2.7% | |
| Mar 2026 | $8.42M | +34.2% | +68.7% | 4.1% | |
| Mar 2026 | $3.43M | -37.6% | -21.0% | 0.8% | |
| Mar 2026 | $912.34K | -7.9% | +25.3% | 1.0% | |
| Mar 2026 | $383K | -48.5% | -24.7% | 0.9% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NVCT) | $53.48M | +8.0% | +21.1% | 3.4% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.